Cyclophosphamide (NSC-26271) Monohydrate

For research use only. Not for use in humans.

目录号:S2057 别名: Cytoxan Monohydrate 中文名称:环磷酰胺一水物

Cyclophosphamide (NSC-26271) Monohydrate Chemical Structure

CAS No. 6055-19-2

Cyclophosphamide (NSC-26271, Cytoxan) Monohydrate是一种氮芥类烷化剂,使烷基连接到DNA的鸟嘌呤碱基。与DNA交联,造成DNA链断裂,引起突变。具有细胞毒性作用。

规格 价格 库存 购买数量  
RMB 785.09 现货
RMB 2375.1 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Cyclophosphamide (NSC-26271) Monohydrate发表文献26篇:

产品安全说明书

DNA alkylator抑制剂选择性比较

生物活性

产品描述 Cyclophosphamide (NSC-26271, Cytoxan) Monohydrate是一种氮芥类烷化剂,使烷基连接到DNA的鸟嘌呤碱基。与DNA交联,造成DNA链断裂,引起突变。具有细胞毒性作用。
体外研究

Cyclophosphamide (CY)是一种化学治疗剂,对免疫系统具有剂量依赖性双重作用。Cyclophosphamide治疗增强细胞凋亡,并降低调控T细胞的稳态增殖。Cyclophosphamide下调GITR和FoxP3的表达,其涉及T(REGs)的抑制活性。[1] Cyclophosphamide增加原代人肝细胞培养物中CYP3A4,CYP2C8,和 CYP2C9蛋白水平,从而提高培养的肝细胞中它们自身的4-羟基化比率。[2]代谢活化存在下,Cyclophosphamide使Salmonella tryphimurium的碱基对取代菌株产生突变,但是在 E. coli显色测试中显示为阴性。代谢活化存在下,Cyclophosphamide能够使各种人工培养的细胞中产生基因突变,染色体畸变,微核和姐妹染色单体互换,并且代谢活化不存在时,会产生姐妹染色单体互换。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BALB/c 3T3 cells M4jKU2N6fG:2b4jpZ4l1gSCjc4PhfS=> MVrJckB3cXS{bzDjfZRwfG:6aXPpeJkhf2G|IHX2ZYx2[XSnZDDpckBud3W|ZTDlcYJzgW9iQlHMRk9kKDOWMzDj[YxteyxiSVO1NF0{Py54IN88US=> NETIdlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97OEezOFEzLz57OEezOFEzRC:jPh?=
HL60 cells M3HUN2N6fG:2b4jpZ4l1gSCjc4PhfS=> M1zkZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRThwN{mg{txO M2TL[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEWwN|A{Lz5{MEi1NFMxOzxxYU6=
BALB/c 3T3 MmDxR5l1d3SxeHnjbZR6KGG|c3H5 NIW3WYRKdiC4aYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCEQVzCM4MhO1R|IHPlcIx{NCCLQ{WwJF0hOzdwNjFOwG0v M3jhRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd6N{exOVAoRjd6N{exOVA9N2F-
T-cells NVzOXYVFUW2vdX7vd5VxeHKnc4PpeoUh[XO|YYm= MVmxNFAhdWdxa3e= MX24JIRigXN? NVPzfXBGUW2vdX7vd5VxeHKnc4PpeoUh[WO2aY\peJkh[WejaX7zeEBOSVZvMTDpcoZm[3SnZDDCRWxDN2NibX;1d4Uh[XO|ZYPz[YQh[XNiVDDj[YxteyC|dYDwdoV{e2mxbjDheEAyODBibXevb4ctKGmyIITy[YF1\WRiODDkZZl{KGKnZn;y[UBqdm[nY4Tpc44h\m:{IESge4Vmc3NibXXhd5Vz\WRiMUSg[IF6eyCyb4P0JIlv\mWldHnvckBjgSCobH;3JIN6fG:vZYTyfS=> NFG5VVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK2PFA5PSd-MUiyOlgxQDV:L3G+
B-cells NXLxXZY{UW2vdX7vd5VxeHKnc4PpeoUh[XO|YYm= MWmxNFAhdWdxa3e= M2LtdFgh\GG7cx?= NXTRb4hVUW2vdX7vd5VxeHKnc4PpeoUh[WO2aY\peJkh[WejaX7zeEBOSVZvMTDpcoZm[3SnZDDCRWxDN2NibX;1d4Uh[XO|ZYPz[YQh[XNiQjDj[YxteyC|dYDwdoV{e2mxbjDheEAyODBibXevb4ctKGmyIITy[YF1\WRiODDkZZl{KGKnZn;y[UBqdm[nY4Tpc44h\m:{IESge4Vmc3NibXXhd5Vz\WRiMUSg[IF6eyCyb4P0JIlv\mWldHnvckBjgSCobH;3JIN6fG:vZYTyfS=> MnPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NkiwPFUoRjF6Mk[4NFg2RC:jPh?=
U87 MG MYPBcpRqfHWvb4KgZZN{[Xl? M3n4e|gxKG2pL3vn M4HBNGFvfGm2dX3vdkBi[3Srdnn0fUBqdiCqdX3hckBWQDdiTVegZ4VtdHNieHXuc4dz[W[2ZXSgcY92e2ViYYSgPFAhdWdxa3esJIl3KGGmbXnubZN1\XKnZDDpckBSOkRieDC1JJNkcGWmdXzl MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR3MES1Okc,OTh2NUC0OVY9N2F-
MX1 NGXGRodCdnSrdIXtc5Ih[XO|YYm= MWGxNlAhdWdxa3e= NWLQXVB1fXBidH:gN{B4\WWtcx?= MYrBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPWEGgZ4VtdHNieHXuc4dz[W[2ZXSgbY4hdnWmZTDtc5V{\SCjZHr1eoFvfCCvb3TlcEBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDtc5V{\SC|dYL2bZZidCC2aX3lJIF1KDF{MDDt[{9s\yxicH:gRmlFKG2nYYP1doVlKHWyIITvJFMhf2Wna4O= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODd{NkWxNkc,OjB5Mk[1NVI9N2F-
U87MG M3PQeWFvfGmlYX7j[ZIh[XO|YYm= M4ezblgxKG2pL3vn NHLMO4M3KGSjeYO= NHq4cWNCdnSrY3HuZ4VzKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gWVg4VUdiY3XscJMhgGWwb3fyZYZ1\WRiaX6gZZRpgW2rYzDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiC|dYDwdoV{e2mxbjDheEA5OCCvZz;r[{whcXZiUULEJIZweiB4IHThfZM> MknzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzME[zO|coRjJzMUC2N|c4RC:jPh?=
NCI-H522 NIrQVG9CdnSrdIXtc5Ih[XO|YYm= MV:1NEBu\y:tZx?= NG\hNWEzQCCmYYnz NGDDS3BCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDV{MjDj[YxteyC6ZX7v[5Ji\nSnZDDpckBD[WykL3OgcpVl\SCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCB3MDDt[{9s\yxiaXegZYRucW6rc4TldoVlKG:wY3Wg[IFqdHliZn;yJFI5KGSjeYOgdoVt[XSrdnWgeI8h[2:wdILvcC=> NX;J[GRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwPVI5PjBpPkK4NFkzQDZyPD;hQi=>
U2932 M2rYTWFvfGm2dX3vdkBie3OjeR?= M1LQeVUxKG2pL3vn M4j4U|Uh[2:wc3XjeZRqfmViZHH5dy=> NVTsTpN5SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gWVI6OzJiY3XscJMhgGWwb3fyZYZ1\WRiaX6gV2NKTCCvb4Xz[UBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6geJVud3JiYoXy[IVvKGG2IEWwJI1oN2upLDDpdEBi\G2rbnnzeIVz\WRiZn;yJFUh[2:wc3XjeZRqfmViZHH5d{Bu\WG|dYLl[EB2eCC2bzDkZZkhPDBicH;zeEBk\WyuIHnuboVkfGmxbh?= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZyNUW5N{c,Ojh4MEW1PVM9N2F-
MDA-MB-231 NUfrVHVGS3m2b4TvfIlkcXS7IHHzd4F6 NGXWVpI1QCCqch?= MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBJd22xIIPhdIlmdnNiKHj1cYFvMSCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFQ5KGi{IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODlizszNMi=> MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4PE8oRkOqRV3CUFww[T5?
K562 MV7DfZRwfG:6aXPpeJkh[XO|YYm= NXHpVGUyPDhiaIK= MkLXR5l1d3SxeHnjbZR6KGGpYXnud5QhUG:vbzDzZZBq\W6|IDjoeY1idiliS{W2NkBk\WyuczDh[pRmeiB2ODDodkBjgSCPVGSgZZN{[XluIFnDOVAhRSByLkG1JO69VS5? M{H1VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg5Nyd-Q3jFUWJNRC:jPh?=
K562 M1S2Z2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NVHGSZc4PDhiaIK= MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFjvcY8he2GyaXXud{ApcHWvYX6pJGs2PjJiY3XscJMh[W[2ZYKgOFghcHJiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4yPTNizszNMi=> NGnzWnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5QC9pPlPoSW1DVDxxYU6=
MCF7 MW\DfZRwfG:6aXPpeJkh[XO|YYm= M4DoR|Q5KGi{ MonER5l1d3SxeHnjbZR6KGGpYXnud5QhUG:vbzDzZZBq\W6|IDjoeY1idiliTVPGO{Bk\WyuczDh[pRmeiB2ODDodkBjgSC2conwZY4h[my3ZTDhd5NigSxiSVO1NEA:KDBwMU[g{txONg>? M4HPclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg5Nyd-Q3jFUWJNRC:jPh?=
HepG2 MnfkR5l1d3SxeHnjbZR6KGG|c3H5 NXHhblA6PDhiaIK= MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBJd22xIIPhdIlmdnNiKHj1cYFvMSCKZYDHNkBk\WyuczDh[pRmeiB2ODDodkBjgSCPVGSgZZN{[XluIFnDOVAhRSByLkK0JO69VS5? NH7sUGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5QC9pPlPoSW1DVDxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
PTEN / pAkt / Caspase 3 / GAPDH; 

PubMed: 23874108     


Western blotting revealed different protein expression in all four intervention groups relative to that in the control group. PTEN and caspase 3 were increased after treatment with cyclophosphamide and/or Chalone 19-peptide. pAkt expression was decreased in the treatment group.

Caspase 3 / Cleaved-Caspase 3 / Cleaved-PARP / Tubulin; 

PubMed: 31429028     


AURKA inhibition induces caspase-independent apoptosis. (a) Induction of caspase-3 and PARP cleavage by immunoblotting in Raji cells treated with PBS (negative control), cyclophosphamide, MLN8237, combination of cyclophosphamide and MLN8237, or etoposide (positive control) at 24 hours.

Nuclear AIF / Cytosolic AIF / TBP / GAPDH; 

PubMed: 31429028     


AURKA inhibition induces caspase-independent apoptosis. (c) Cytosolic and nuclear AIF levels over time in Raji cells treated with MLN8237 at 8, 16, and 24 hours.

LC3B I / LC3B II / GAPDH; 

PubMed: 31429028     


AURKA inhibition reverses autophagy. (a) LC3B-II levels by immunoblotting in chemoresistant (Raji) cells treated with PBS (negative control), cyclophosphamide, MLN8237, or combination of cyclophosphamide and MLN8237, or etoposide (positive control) at 48 hours.

23874108 31429028
Growth inhibition assay
Cell Viability; 

PubMed: 31429028     


Baseline characteristics of chemosensitive (Ramos) and chemoresistant (Raji) Myc-positive cell lines. (c) Cytotoxicity assay of cyclophosphamide, MLN8237, or the combination in chemoresistant Raji cells.

Tumor Volume; 

PubMed: 24681847     


(B–C) MUC1.Tg mice bearing (B) MC38/MUC1+ s.c. tumors or (C) Panc02/MUC1+ orthotopic tumors were randomized and treated with control liposomes, cyclophosphamide and tecemotide, cyclophosphamide and NHS-muIL12, or the combination of cyclophosphamide, tecemotide, and NHS-muIL12 (n = 9-10 mice per group).

Tumor Volume; 

PubMed: 21069336     


In vivo antitumour activity of the combination of fisetin with cyclophosphamide. Twenty mice bearing bilateral Lewis lung tumours were randomly assigned to four groups of 5 mice as follows: control, solvent alone (squares); fisetin, 223 mg/kg i.p. on days 4 to 8 and days 11, 12, 14 (triangles); cyclophosphamide, 30 mg/kg s.c., on days 4, 5, 7, 8 (diamonds); and, the combination of cyclophosphamide and fisetin (solid circles), both administered at the same dose and schedule when used alone. Tumour volumes were determined as described in Materials and Methods. Mean ± SEM.

31429028 24681847 21069336
IHC
tumor cell invasion; 

PubMed: 23874108     


(A) Animal model control group with tumor cell wear through skin squamous epithelium, HE × 120. (B) Animal model control group with tumor cell invasion to skeletal muscles, HE × 120. (C) Animal model control group with tumor cells actively around blood vessels, HE × 120. (D) Animal model control group showing pulmonary metastasis, HE × 460. (E) Cyclophosphamide group with hemorrhage and necrotic tissue in liver, HE × 460. (F) Chalone 19-peptide group showing hydropic degeneration in hepatic cells, HE × 460. (G) Cyclophosphamide 100 mg/kg and Chalone 19-peptide combined treatment group showing fatty degeneration of tumor cells, HE × 460. (H) Cyclophosphamide 50 mg/kg and Chalone 19-peptide combination treatment group showing punctuate phagocytic infiltration, HE × 460. (I) Control group with slight phagocytic infiltration, HE × 460.

TUNEL / Caspase 3; 

PubMed: 23874108     


TUNEL analysis and immunohistochemistry testing of caspase 3 showing apoptosis in all four intervention groups relative to controls. (A) Immunohistochemistry testing of caspase 3. (a1) Cyclophosphamide group, (a2) Chalone 19-peptide group, (a3) Cyclophosphamide 100 mg/kg and Chalone 19-peptide combined treatment group, (a4) Cyclophosphamide 50 mg/kg and Chalone 19-peptide combined treatment group, and (a5) control group (×460). (B) Immunofluorescence testing of TUNEL. (b1) Cyclophosphamide group, (b2) Chalone 19-peptide group, (b3) Cyclophosphamide 100 mg/kg and Chalone 19-peptide combined treatment group, (b4) Cyclophosphamide 50 mg/kg and Chalone 19-peptide combined treatment group, and (b5) control group (×460). (C) Immunohistochemistry testing of TUNEL. (c1) Cyclophosphamide group, (c2) Chalone 19-peptide group, (c3) Cyclophosphamide 100 mg/kg and Chalone 19-peptide combined treatment group, (c4) Cyclophosphamide 50 mg/kg and Chalone 19-peptide combined treatment group, and (c5) control group (×460).

PTEN / pAkt / PCNA; 

PubMed: 23874108     


Immunohistochemistry revealing different proteins in intervention groups relative to controls. Micrographs of cells after immunohistochemistry showing that PTEN, pAKt, and proliferating cells were produced by the different groups. After treatment with cyclophosphamide and/or Chalone 19-peptide, PTEN was increased. pAkt and PCNA were decreased and necrosis was observed (×460). (A) Immunohistochemistry testing of PTEN. (a1) Cyclophosphamide group, (a2) Chalone 19-peptide group, (a3) Cyclophosphamide 100 mg/kg and Chalone 19-peptide combined treatment, (a4) Cyclophosphamide 50 mg/kg and Chalone 19-peptide combined treatment group, and (a5) control group. (B) Immunohistochemistry testing of pAkt. (b1) Cyclophosphamide group, (b2) Chalone 19-peptide group, (b3) Cyclophosphamide 100 mg/kg and Chalone 19-peptide combined treatment group, (b4) Cyclophosphamide 50 mg/kg and Chalone 19-peptide combined treatment group, and (b5) control group. (C) Immunohistochemistry testing of PCNA. (c1) Cyclophosphamide group, (c2) Chalone 19-peptide group, (c3) Cyclophosphamide 100 mg/kg and Chalone 19-peptide combined treatment group, (c4) Cyclophosphamide 50 mg/kg and Chalone 19-peptide combined treatment group, and (c5) control group.

ovary of mice; 

PubMed: 32308430     


The effect of testosterone in mice treated with cyclophosphamide. Notes: (A) H&E staining of the ovary of mice treated with phosphate-buffered saline (PBS), cyclophosphamide (CPA) and cyclophosphamide plus testosterone (Ts). There are abundant primordial follicles (black arrows) and a few atresia (white arrows) in the ovaries of PBS-treated mice. In contrast, there are many atresia (white arrows) in the ovaries of CPA-treated mice. A small number of primordial follicles (black arrows) were found. In the ovaries of CPA plus Ts-treated mice, abundant primordial follicles (black arrows) and a few atresia (white arrows) were found. Bar = 100 μm.

Caspase-3; 

PubMed: 32308430     


The immunohistochemical analysis of cleaved Caspase-3 in mouse ovary. Notes: (A) The expression of cleaved-caspase-3 (Cl-Caspase-3) on immunohistochemistry. There are many follicles in mouse ovaries (black arrows). A large number of Cleave caspase-3-positive cells (white arrows) were found in the follicles of cyclophosphamide (CPA)-treated mice. In contrast, there were fewer Cl-Caspase-3 positive cells in the follicles in phosphate-buffered saline (PBS)-treated mice and cyclophosphamide plus testosterone (Ts)-treated mice. Bar = 100 μm.

23874108 32308430
Immunofluorescence
pAKT / pERK; 

PubMed: 31654636     


Representative images of phosphorylated AKT (pAKT) and phosphorylated extracellular signal-regulated kinase (pERK) immunostaining in keratinocyte growth factor (KGF)–pretreated bladders 1 day after cyclophosphamide injection.

Ki-67 / UPK3 / KRT5 / pERK; 

PubMed: 31654636     


Representative images and graphs of urothelial proliferation and phosphorylated extracellular signal-regulated kinase (pERK) immunostaining in keratinocyte growth factor (KGF)–pretreated bladders 6 hours after cyclophosphamide injection.

Ki-67 / KRT14 / KRT5; 

PubMed: 31654636     


Representative images and graphs of urothelial proliferation in keratinocyte growth factor (KGF)–pretreated bladders 1 day after cyclophosphamide injection.

autophagy levels; 

PubMed: 31429028     


(c) Representative photomicrograph (400 X) of autophagy levels in Raji cells stained with after treatment acridine orange staining with PBS (negative control), cyclophosphamide, MLN8237, or combination of cyclophosphamide and MLN8237. The accumulation of acidic vesicular organelles, which emit bright red/orange fluorescence correspond to autophagy activity.

31654636 31429028
体内研究 Cyclophosphamide会使大鼠,小鼠和中国仓鼠体内产生染色体损伤和微核,并且在小鼠斑点试验和Muta小鼠转基因lacZ构建体中产生基因突变。[3] Cyclophosphamide,以确定的顺序加入到GM-CSF-分泌的,neu-表达的全细胞疫苗中,能够增强疫苗的潜在作用以延缓neu转基因小鼠体内的肿瘤生长。Cyclophosphamide通过增强疫苗的功效,而不是通过对癌细胞的直接细胞溶解作用发挥它的作用。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 55 mg/mL (197.06 mM)
Water 7 mg/mL (25.08 mM)
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 279.1
化学式

C7H15Cl2N2O2P.H2O

CAS号 6055-19-2
储存条件 粉状
溶于溶剂
别名 Cytoxan Monohydrate

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04757337 Recruiting Drug: Doxorubicin|Drug: Cyclophosphamide Advanced Soft-tissue Sarcoma|Metastatic Soft-tissue Sarcoma UNICANCER July 2021 Phase 3
NCT04656951 Recruiting Drug: Daratumumab Multiple Myeloma University of Cologne|Janssen-Cilag G.m.b.H June 1 2021 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Why S2057 Cyclophosphamide Monohydrate shows no activity in vitro assays?

  • 回答:

    Cyclophoshamide is a prodrug and needs Pytochrome P450 to convert it to the active form: 4-hydroxy cyclophosphamide. It is widely used in vivo, if you are going to use it in vitro, you'll have to supplement Pytochrome P450 exogenously.

免费分装抑制剂
Tags: 购买Cyclophosphamide (NSC-26271) Monohydrate | Cyclophosphamide (NSC-26271) Monohydrate ic50 | Cyclophosphamide (NSC-26271) Monohydrate价格 | Cyclophosphamide (NSC-26271) Monohydrate DMSO溶解度 | 采购Cyclophosphamide (NSC-26271) Monohydrate | Cyclophosphamide (NSC-26271) Monohydrate生产 | Cyclophosphamide (NSC-26271) Monohydrate 小鼠 | Cyclophosphamide (NSC-26271) Monohydrate化学结构 | Cyclophosphamide (NSC-26271) Monohydrate分子量 | Cyclophosphamide (NSC-26271) Monohydrate molecular weight | Cyclophosphamide (NSC-26271) Monohydrate说明书 | Cyclophosphamide (NSC-26271) Monohydrate供应商 | Cyclophosphamide (NSC-26271) Monohydrate体内 | Cyclophosphamide (NSC-26271) Monohydrate细胞系 | Cyclophosphamide (NSC-26271) Monohydrate浓度 | Cyclophosphamide (NSC-26271) Monohydrate nmr | Cyclophosphamide (NSC-26271) Monohydrate核磁 | Cyclophosphamide (NSC-26271) Monohydrate半数抑制浓度 | Cyclophosphamide (NSC-26271) Monohydrate体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID